التفاصيل البيبلوغرافية
| العنوان: |
Peptide-functionalized gold nanoparticles for boron neutron capture therapy with the potential to use in Glioblastoma treatment. |
| المؤلفون: |
Zhang, Zhicheng1,2 (AUTHOR), Wang, Xin1 (AUTHOR), Dai, Qi2 (AUTHOR), Qin, Yaxin1,3 (AUTHOR), Sun, Xiaoyan1 (AUTHOR), Suzuki, Minoru4 (AUTHOR), Ying, Xiaoying1,5 (AUTHOR) yingxiaoying@zju.edu.cn, Han, Min1,2,3,4 (AUTHOR) hanmin@zju.edu.cn, Wei, Qichun2 (AUTHOR) qichun_wei@zju.edu.cn |
| المصدر: |
Pharmaceutical Development & Technology. Oct2024, Vol. 29 Issue 8, p862-873. 12p. |
| مصطلحات موضوعية: |
BORON-neutron capture therapy, GOLD nanoparticles, GLIOBLASTOMA multiforme, GLIOMAS, LABORATORY mice |
| مستخلص: |
Glioblastoma is a highly aggressive glioma with limited treatment options. Boron neutron capture therapy (BNCT) offers a promising approach for refractory cancers, utilizing boron-10 (10B) and thermal neutrons to generate cytotoxic particles. Effective BNCT depends on selective targeting and retention of 10B in tumors. Current BNCT drugs face issues with rapid clearance and poor tumor accumulation. To address this, we developed gold nanoparticles (AuNPs) functionalized with cyclic arginine-glycine-aspartic acid (cRGD) peptides as a nanocarrier for Sodium Mercaptododecaborate (BSH), resulting in AuNPs-BSH&PEG-cRGD. In vitro, AuNPs-BSH&PEG-cRGD increased 10B content in GL261 glioma cells by approximately 2.5-fold compared to unmodified AuNPs-BSH&PEG, indicating enhanced targeting due to cRGD's affinity for integrin receptor αvβ3. In a subcutaneous glioma mouse model, 6 h post-intratumoral administration, the 10B concentration in tumors was 17.98 μg/g for AuNPs-BSH&PEG-cRGD, significantly higher than 0.45 μg/g for BSH. The tumor-to-blood (T/B) and tumor-to-normal tissue (T/N) ratios were also higher for AuNPs-BSH&PEG-cRGD, suggesting improved targeting and retention. This indicates that AuNPs-BSH&PEG-cRGD may enhance BNCT efficacy and minimize normal tissue toxicity. In summary, this study provides a novel strategy for BSH delivery and may broaden the design vision of BNCT nano-boron capture agents. [ABSTRACT FROM AUTHOR] |
|
Copyright of Pharmaceutical Development & Technology is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Business Source Index |